IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.

Trial Profile

IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Imatinib (Primary) ; Hydroxycarbamide
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 02 May 2012 Planned number of patients changed from 76 to 80 as reported by European Clinical Trials Database.
    • 07 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top